UK cataract dataset audit reveals medications more likely to cause complications during surgery

Article

Clopidogrel and warfarin are associated with a significant increase in minor complications of sharp needle and subtenon?s cannula local anaesthesia but are not associated with sight-threatening complications, according to a study published online ahead of print by Eye.

Clopidogrel and warfarin are associated with a significant increase in minor complications of sharp needle and subtenon’s cannula local anaesthesia but are not associated with sight-threatening complications, according to a study published online ahead of print by Eye.

Robert Johnson from the Gloucestershire Eye Department, Cheltenham General Hospital, UK, and colleagues carried out a study to establish the prevalence of aspirin, dipyridamole, clopidogrel and warfarin use in patients undergoing cataract surgery and to compare local anaesthetic and intraoperative complication rates between users and non users. The Cataract National Dataset was extracted and anonymized on 48,862 operations at 12 National Health Service (NHS) Trusts using electronic patient records between 2001 and 2006.

In all, 28.1% of patients were taking aspirin, 5.1% warfarin, 1.9% clopidogrel and 1% dipyridamole. The incidence of any complication of a sharp needle or subtenon’s cannula local anaesthetic block was increased in patients taking clopidogrel (8%, p<0.0001) or warfarin (6.2%, p=0.0026) versus non-users. However, there was no increase in potentially sight-threatening complications. The incidence of subconjunctival haemorrhage was also increased in patients taking clopidogrel (4.4%, p<0.0001) or warfarin (3.7%, p<0.0001) versus non-users. The recording of operative complication was increased in those taking clopidogrel (7.3%, p=0.0002) versus non-users but the haemorrhagic operative complications of choroidal/suprachoroidal haemorrhage and hyphaema were not significantly increased.

The authors concluded that there is a significant increase in minor complications in cataract surgery patients taking clopidogrel and warfarin.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.